In this article, the general principles of genetically modified (GM) plant risk assessment and the regulatory framework for contained use and open field production of plant-made pharmaceuticals/plant-made industrials (PMP/PMI) are described. While significant progress has been made for the containment grown (plant cell culture) production of PMPs, with the first regulatory approval made by the FDA in 2012, the commercialization of medicinal or industrial products produced in the field has yet to emerge in either Europe or the US. In the current paper, we discribe the regulatory environment in Europe and the US surrounding GM crops, and provide case studies for experimental field releases of PMP and PMI producing plants in both regions. Suggestions for reducing the regulatory burden for GM plants will be discussed, also in light of the emerging new technologies to modify the genetics of plants. Since regulations surrounding the commercialization of GM crops are very costly and not appropriate for most of the PMP/PMI applications in Europe, we propose that amendments to the EU Directive 2001/18/EC are necessary to allow for the commercialization of products from GM plants without the need of an 'authorization'. To fully acknowledge the overall outcome of adopting plants to produce PMP/PMI, the conclusion is that broader and more balanced legislative oversight is needed in Europe; while specific legislation is not needed in the US.
INTRODUCTION
Plant genetic modification (GM), developed over the past twenty five-years, has been applied to input traits, to improve plant production in the form of herbicide and pest resistant crops, as well as to output traits in the form of nutritional improvement (such as Golden Rice), industrial proteins (e.g. cellulase, and trypsin) and pharmaceuticals and vaccines (Plant Molecular Farming -PMF). The benefits of input and output traits are now extensively documented, yet the full exploitation of this technology remains hindered by the long lead times associated with such emerging R&D technology combined with the timescales involved in introducing these new traits into local adapted varieties. One of the biggest barriers to the adoption of this technology into the commercial sector is the intense scrutiny of these new plant varieties by regulatory agencies and the public, and the costs associated with regulatory approval. The average cost for having GMOs approved in Europe has been estimated at 7-10 million Euros per event [1] . These costs mainly accrue from the large number of studies which the applicant companies have to present to the European Food Safety Authority (EFSA). The 30 approvals (including for imports) having been granted by April 2011 represent total costs to companies of between 210 and 300 million [2] .
PMF consists of using plants as production platforms for the synthesis of compounds for pharmaceutical or industrial purposes. PMF has been presented as a convenient way to produce molecules of interest on a large scale at low costs. Other benefits associated with the use of plants are; rapid scaling up, convenient storage of raw material (in the form of seed) and less concern over human pathogen contamination. However, in order for any impact to be realized from this research, these laboratory experiments must *Address correspondence to this author at the John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK; Tel: +44 (0) 1603 450547; Fax: +44 (0) 1603 450045; E-mail: penelope.sparrow@jic.ac.uk move ahead to the field or production arena. As with all GM plants, those intended for molecular farming must go through a thorough risk assessment before they can be used in the field. In that respect, whereas existing guidance on the environmental risk assessment of GM plants for food/feed uses is considered adequate to also cover GM plants for non-food/feed uses [3] , PMF raises novel questions that might trigger a need for specific biosafety considerations due to the nature of the proteins to be expressed.
Commercialization has many hurdles including not only the science and associated intellectual property to protect the inventions, but also market realities and government regulations. As each GM plant moves from the laboratory to scaled-up greenhouse production or to the field, issues emerge that trigger additional oversight for environmental release or ultimate use by humans. In this review, we outline the current state of play regarding the risk assessment and regulations surrounding GM plants and how the current regulatory systems are adapting to accommodate PMF.
GENERAL PRINCIPLES OF GM PLANT RISK ASSESS-MENT 2.1. Interplay of Risk Assessment, Risk Management and Risk Communication
In different countries across the world (termed hereafter as "jurisdictions"), GM plants and their derived food and feed products are subject to a risk analysis before they can be used for experimental or commercial uses. The case-by-case risk analysis encompasses all components of risk, and consists of assessment, management, and risk communication. In risk assessment, potential adverse impacts associated with a specific activity are scientifically characterized on a case-by-case basis. Risks are identified from plausible sets of circumstances that may result in harm to human and animal health or the environment, and subsequently the level of risk is estimated on the basis of the seriousness and chance of harm. Risk management evaluates, selects, and implements plans or actions to ensure risks are appropriately managed. Thereby, policy alternatives to accept, minimize, or reduce the characterized risks are weighed and, if needed, appropriate prevention and control options are selected. Because risk managers and regulators rely on risk assessments to make an informed decision on whether or not to approve a certain use of a GM plant, it should explain clearly what assumptions have been made during the risk assessment, and what is the nature and magnitude of scientific uncertainties associated with the characterized risks. The decision whether a certain risk is acceptable and/or tolerable under a particular set of conditions is not part of the risk assessment itself, but part of the wider risk analysis, as this choice is not only based on scientific criteria, but also involves political, social, cultural and economic considerations -for example in the case of PMF it will be critical that these crops should not become mingled with commodity crops. While this is also the case for agricultural GM crops, the perceived public backlash is likely to be greater for a pharmaceutical crop. Risk management is also functionally and temporally separate from risk assessment in order to reduce any conflict of interest and to protect the scientific integrity of risk assessment [4] . Risk communication is defined as an interactive exchange of information and opinions on risk throughout risk analysis, between risk assessors, risk managers and other interested parties. It includes the explanation of risk assessment findings and of the basis upon which risk management decisions are made [5] .
Harm refers to adverse effects to the human and animal health or the environment, while risk is recognized as a function of the probability of an adverse effect occurring to human and animal health or the environment and its seriousness, following exposure to a hazard due to an activity i.e. the possible intended use(s) of a GM plant. Without hazard (i.e., the potential of an agent or situation to cause harm), there is no harm and thus no risk. It is therefore crucial to distinguish risk from hazard in risk assessment, as both terms have different meanings. Various studies, assessing the impact of GM plants, have postulated dire risks when all they have done is characterized either a hazard associated with the use of GM plants, or an exposure to the GM plant without demonstrating whether this exposure is hazardous (reviewed by [4] ). Such studies rarely link hazard to exposure, and in effect confuse hazard or exposure with risk.
Risk Assessment Principles and Concepts
Regulatory requirements involve the consideration of a range of issues (areas of risk) relevant to the overall risk assessment, in order to determine the impact of the GM plant on human and animal health or the environment relative to the comparable non-GM crop, and thus its relative safety [6, 7, 8, 9] . These include amongst others (and differently required in different jurisdictions): (1) molecular characterization of the GM plant, which provides information on the structure and expression of the insert(s) and on the stability of the intended trait(s); (2) the comparative analysis of compositional, phenotypic and agronomic characteristics to identify intended and unintended changes in the GM plant; (3) the toxicological assessment of the genetic modification, which addresses the impact on human and animal health of biologically relevant change(s) in the GM plant and/or derived food and feed resulting from the genetic modification; (4) the assessment of the allergenic potential of the novel protein(s) (in the case of PMF, this assesment would determine whether approval would be granted for a field release); (5) the nutritional assessment, which aims to demonstrate that the food and feed derived from a GM plant is not nutritionally disadvantageous to humans and/or animals; (6) potential changes in the persistence (weediness) and invasiveness ability of the GM plant; (7) potential for gene transfer; (8) interactions between the GM plant and target organisms; (9) interactions between the GM plant and non-target organisms; (10) potential adverse effects on biogeochemical processes; (11) impacts of altered farm management practices associated with the cultivation of the GM plant; (12) potential interactions with the abiotic environment; and (13) the scientific quality of the proposed post-market (environmental) monitoring plan [8, 9, 10] . Moreover, an assessment of direct and indirect, as well as immediate and delayed, including cumulative long-term effects is required in several jurisdictions. Now it could be argued that a lot of the criteria set out above, would not be applicable to PMF as these crops are not designed to enter the food chain. However, if they are engineered into a food crop then these assessments will be necessary, as part of the precautionary approach -i.e. what if they did become mixed in the food chain. EFSA have produced guidance notes on the Risk Assessment for GM crops for non-food/feed uses to address some of these differences [3] .
Even though there are considerable differences in regulatory requirements for GM plants and derived products, priorities in terms of protection goals, as well as risk terminology among jurisdictions globally, most risk assessments: (1) follow sequential steps; (2) are science-based, where quantitative information is available, and use qualitative information in the form of expert judgment; (3) use a comparative approach whereby the level of risk is estimated through comparison with a non-GM counterpart; (4) are case-specific; (5) are iterative and, in a transparent manner, examine previous conclusions in light of new information; and (6) follow a tiered approach. For a more detailed account of GM risk assessment we refer you to [11] .
NEW BREEDING TECHNIQUES IN MOLECULAR FARMING AND IMPLICATIONS FOR THE CURRENT EU REGULATORY SYSTEM
Several new breeding techniques (NBT) are currently under way which differ substantially from the transgenic (GM) techniques that have been used in the last two decades. For some of them the regulatory framework in the EU may no longer be feasible, resulting in a legislative/regulatory uncertainty concerning these techniques. In 2007, due to a mandate of the EU commission a new techniques working group (NTWG) was established in which experts from competent authorities of several European countries evaluated the following eight NBTs: Oligo-directed mutagenesis (ODM); Zinc finger nuclease technology (ZFN); Cisgenesis/intragenesis; RNA-dependent DNA methylation (RdDM); Grafting (on GM rootstock); Reverse breeding; Agro-infiltration; and Synthetic genomics. In 2012, the working group finished the evaluation and circulated its opinion for comments. In 2010, a working group led by the Joint Research Centre of the EU commission started to develop a study concerning the same eight techniques. The final report of this study was published last year [12] . In 2011 on request of DG SANCO, the EFSA also set up a working group to determine whether the existing guidance on risk assessment is appropriate concerning NBTs. The EFSA working group will be providing its opinion one by one, starting with cisgenesis and intragenesis [13] .
Cisgenesis/intragenesis technique refers to the integration of genes into a plant genome: a transgenic (GM) approach, but restricting the source of the genes to sexually compatible crossing partners of the recipient plant. By this approach only cisgenesis produces progeny which can arise by chance by a conventional breeding process (CBP), whereas intragenesis always produces progeny which cannot be achieved by CBP. As the process itself introduces foreign DNA which is capable of replication and inheritable, the technique might be considered to be regulated by GMO legislation. If a cisgene without a selection marker or other foreign DNA-sequences is transferred using nuclease technique (see , the resulting plant is nearly indistinguishable from the one derived through a CBP and meets the criteria of self-cloning. In this case, which is described in Annex II, part A of Directive 2009/41/EC it might be falling outside the scope of the GMO legislation.
Oligo-directed mutagenesis is a technique using short oligonucleotides as a tool to induce targeted alterations in the genome ranging from one to a few adjacent nucleotides. The alterations are caused by mispairing of nucleotides and the subsequent DNA repair by the host cell. The ODM technique can be used, e.g., for induction of herbicide resistance in tobacco due to point mutations [14] . However, because the ODM technique does not introduce recombinant DNA into the plant which is capable of replication, it is discussed by the NTWG to be not regulated by the GMO legislation or to be excluded from Directive 2001/18/EC (Annex IA, Part 1).
The aim of RNA-dependent DNA methylation is the induction of gene silencing via promoter methylation of target genes. Depending on the delivery method of the DNA which encodes for the silencing RNAs, the expression can be transient thus only inducing epigenetic changes of the genome by the RNA silencing pathway. If the DNA coding for the silencing RNA is stably integrated into a plant genome it is regulated by current GMO legislation. If only transient expression occurs, it should not be in the scope of the GMO legislation because methylation of nucleotides is not considered to be an alteration of genomic material.
Grafting with GM scions or rootstocks can be used for the transient expression of proteins or other effectors like RNAs to induce, e.g., enhanced pathogen resistance. This technique can be performed using a non-GM scion onto a GM rootstock or vice versa. In both cases the resulting plant is a chimeric plant which falls within the scope of the GMO legislation. The fruits, seeds or offspring of a GM scion are also regulated by GMO legislation, whereas the fruits, seeds or offspring derived from a non-GM scion grafted onto a GM rootstock might not fall under the scope of Directive 2001/18/EC. The Reverse breeding technique is able to reconstitute the parental lines starting with an elite F1 hybrid whose genetic material is unknown [15, 16] . Reverse breeding combines several other techniques, i) RNAi to suppress meiotic recombination; ii) tissue culture to regenerate plants from cells; and iii) the double haploidization technique to create double haploid plants which are used as the respective parental lines to produce new elite F1 hybrids. During this procedure a transgenic step can be included but the final plant lines are non-transgenic and therefore might be considered as falling outside the scope of the GMO legislation.
Synthetic genomics aims to synthesize large DNA molecules followed by transformation in a recipient structure. As the application of this technique to genetically modify plants is in a very early stage, possible future implications have been evaluated. Only if the synthesized DNA is assembled to result in an entity which is a microorganism will it fall under the scope of Directives 2009/41/EC (Annex I Part A) and 2001/18/EC (Annex 1A Part 1).
Several of the NBTs are already in use or planned to be used for general plant breeding in the near future. The following two NBTs especially, may have great benefits for molecular farming purposes: Zinc finger nuclease technology and Agro-infiltration.
Zinc finger nuclease technique was the original term describing a new technique which uses an unspecific nuclease (usually FokI) coupled to a sequence specific DNA binding element, the zinc finger. The restriction activity is directed to a certain locus in the genome of an organism by the zinc finger binding activity. After induction of a double strand break (DSB), the repair is done completely by the host cell. The working group of new techniques discriminated between three different ways how ZFN can be used. ZFN-1: Without any additional DNA homology, the DSB will be repaired in almost all cases by the non-homologous end joining pathway of the cell. This will result in point mutations or small InDels at the DSB site. ZFN-2: Adding short DNA sequences which are differing only in a few nucleotides to the genomic sequence around the DSB can result in a repair which copies these differences in the genomic sequence. ZFN-3: To enable targeted integration by homologous recombination, long DNA sequences (500-1000 nt) with homology nearby the DSB site have to be present on the targeting construct.
Two other nuclease techniques have been developed to achieve the same task by slightly differing means, meganucleases (MN) and transcription activator like effector nucleases (TALENs) [17, 18] . In general all three types of site directed nucleases (SDN) perform two functions: i) specific DNA recognition and binding and ii) introduction of a DSB in or nearby the bound sequence. This DSB greatly enhances the chance for homologous recombination and thereby offers the opportunity to integrate any DNA sequence specifically at a targeted locus instead of elsewhere in the genome [19, 20] . Therefore, SDN technique allows choosing or designing a genomic locus which possesses the best performance for stable and high expression of, e.g., PMP genes.
The nuclease techniques described under ZFN-1 and -2 used for gene alteration with only point mutations or a few nucleotide changes, might be considered to be not regulated by GMO legislation as far as no foreign DNA is integrated in the plant cell. The outcome of ZFN-1 and -2 is indistinguishable from natural mutations. ZFN-3 technique used for gene integration is covered by the existing guidance for risk assessment and GMO legislation as it does not differ in its mode of action from the integration of genes by transgenesis. However, nuclease technique in general greatly enhances the accuracy of gene integration in a preselected target locus, thereby minimizing unattended side effects which might result in an easier risk assessment.
The term Agro-infiltration (or Agro-inoculation) means that a plant or plant tissue is infiltrated with a liquid Agrobacterium sp. suspension. The Agrobacterium delivers T-DNA from which genetic material is expressed locally and transiently at high levels in the plant to produce a specific protein. Agro-infiltration has been used in research for, e.g., the transient expression of resistance genes from wild grape in susceptible grapevine cultivars or for the expression of artificial micro RNAs conferring resistance to potato virus X and Y [21] . Concerning the production of pharmaceutical proteins in plants, e.g., Artemisinin precursors as well as IgG or IgM antibodies have been produced in Nicotiana benthamiana resulting in yields of 40 to about 600 mg/kg of fresh weight [22] [23] [24] [25] .
As the technique described does not aim for progeny of the inoculated plant tissue, the only GMO involved in the process is the Agrobacterium. Therefore, Agro-infiltration is covered by the currently existing legislation and risk assessment as GMM in plants. Usually the plants or the plant tissue are destroyed after the experiment. Progeny derived from this plant material in which absence of stably integrated DNA is proven might not be considered a GMO and therefore might not fall under the scope of the GMO legislation. Agro-infiltration approaches for PMP production, of containment grown plants, are beginning to see investment. Two companies leading in this area are Kentucky Bioprocessing (www.kbpllc.com/) and Medicago (www.medicago.com/), the later now being in scale up for phase II clinical trials of their avian flu vaccine, produced using transient expression systems.
CONDITIONS FOR MOLECULAR FARMING IN EUROPE 4.1. Regulatory Framework for Contained and Open Field use of GM Plants
The European Union (EU) is considered to have the toughest and most stringent legislation on GM products and commodities in the world. The enforcement of such legislation has three main objectives: to protect human and animal health and the environment; to guarantee consumers' freedom of choice without misleading consumers/users; and to create an internal market allowing the free movement of safe and healthy GM products within the EU, thus avoiding unequal competition and trade impediments between and within EU Member States.
The EU regulatory approach is precautionary, process-related, and includes mandatory labelling and traceability requirements for food and feed products derived from GM plants, unprocessed or processed. Only non-food GM products (unseeded), such as textile or other industrial products are not subject to any requirements for labelling.
EU legislation is adopted through a system of interactions between the three main EU institutions: the European Parliament, the Council of the European Union (i.e., representatives of all the EU Member States at the ministerial level), and the European Commission. In most cases, the European Commission initiates legislative proposals that are decided jointly by the Council and the European Parliament; the most common legislative measures are Regulations (acts that are binding in their entirety and are immediately applicable throughout the EU) and Directives (acts that require the modification or establishment of national measures, generally for harmonization purposes).
In the early 1990s, two European Directives for the use of GMOs were adopted: Directive 90/219/EEC (which has since been amended by Directive 98/81/EEC, and more recently 2009/41/EC), which regulated the contained use of GM micro-organisms; and Directive 90/220/EEC (which has since been replaced by Directive 2001/18/EC) which regulated the deliberate release of GMOs into the environment, covering both the release for research purposes (part B) and for commercial use as or in products (part C). This triad reflects the stepwise process GM plants go through, beginning with experiments under contained use (e.g., laboratory, greenhouse), through experimental release, up to the placing on the market. According to the step-by-step principle, the containment of GMOs can be reduced and the scale of release increased gradually, if assessment of earlier steps indicated that the next step can be taken. Thus broadly speaking there are two categories of authorization: (1) for the contained use (i.e., those grown in laboratories, glasshouses, or fully contained facilities such as cell culture systems); and (2) for the 'deliberate release into the environment', either for experimental purposes or for commercial cultivation. If the GMO is intended for food and/or feed uses, its potential uses are regulated under the scope of GM food and feed Regulation (EC) 1829/2003.
When the end product of a molecular farming activity is a pharmaceutical, the safety or toxicological aspects of the product and its uses fall under Regulation (EC) 726/2004 on medicinal products.
Contained use of GM Plants
Within Europe the contained use of all GMOs (which includes GM bacterial, mammalian and plant cultures) as previously mentioned, is covered by Directive 2009/41/EC. Contained use covers the initial production of a GMO in the laboratory, as well as the use, storage, transport and destruction of the GMO. Any organization wanting to produce or handle GMOs must notify the relevant competent authorities of their intention to use their premises for contained use activities for the first time. It then becomes the responsibility of the organization to ensure that the appropriate risk assessments are in place, and the appropriate level of containment is selected to minimize any potential risks to negligible or low. In the case of growing a GM plant in glass house containment, for example, measures would be put in place: -To reduce the likelihood of, or prevent insects or rodents from entering the glasshouse -thereby minimizing any potential transfer of material, i.e., pollen or seed out of the glasshouse and reducing any potential unintended effects resulting in exposure of these groups to the plants; When GM plants are used to produce therapeutic or industrial proteins in plant suspension cell systems, containment in enclosed sealed bioreactors would in some cases simplify the risk assessment and biosafety issues. These types of culture systems are likely to also be more familiar to the current pharmaceutical industry (cf., use of mammalian and bacterial cell culture systems). In 2006, the first PMP, a vaccine for poultry (against Newcastle disease) gained regulatory approval from the US Department of Agriculture. Although this poultry vaccine remained a proof-of-concept and was never sold, it paved the way for future PMF. Indeed, the first plantmade biologic, for human use, to gain [US] regulatory approval was produced in a carrot cell system (for the production of Elelyso, an enzyme to treat type 1 Gaucher's disease) by the Israel-based Protalix BioTherapeutics, which gained FDA regulatory approval in May 2012 (http://www.protalix.com/productdevelopment/elelyso.asp).
Meanwhile, in Europe an EU-funded project that ran from 2004-2011 (www.pharma-planta.net) saw the first regulatory approval for a PMF product to enter phase 1 clinical trial in humans. The product was an anti-HIV monoclonal antibody; using whole tobacco plants grown in containment as the platform. The choice of host plant and growing environment was somewhat determined as the EU program developed, in order to meet the least regulatory resistance, and is further discussed later. Although plants have been shown to be potentially useful for the production of therapeutic proteins, they are at a relatively early stage of development and more needs to be done so that they can be used to produce proteins in a consistent manner. Another EU funded project, (www.comofarm.org), was established to address these issues, and to look at a range of containment platforms (hydroponic plants, root culture, cultivated moss and cell suspension culture) across a range of plant species. Ultimately, the results from the CoMoFarm (contained molecular farming) project, which concludes at the end of 2012, aims to help reduce the costs involved in the production of pharmaceutical and industrial proteins and ensure that pharmaceuticals from plants are produced to the highest possible standards.
However, to fully exploit the claims of using plants as production vehicles for cheap production of therapeutic and industrial proteins (especially the lower value proteins) it may be desirable for plants to be cultivated on a larger scale than containment-grown approaches. For example, it has been estimated that one acre of safflower engineered to produce insulin by the Canadian company SemBioSys, could produce more than one kilogram of insulin, enough to treat 2,500 diabetic patients for one year. That means just 16,000 acres of safflower could meet the world's total demand each year.
Open field use of GM Plants
Growing GM plants in the field for experimental purposes constitutes a 'deliberate environmental release' and as such requires prior notification under the Directive 2001/18/EC to the local competent authority of the EU Member State in which the proposed field release was intended. Such notifications must include details about the host plant, the introduced trait, the purpose of the release and details of the exact location and size of the trial, an environmental risk assessment and details of the risk management strategies [26] . Once the notification has been sent to the competent national authority it is passed on to a scientific advisory committee, who will look at the risk assessments and potential environmental impacts and assess if the trial would pose a threat to health or the environment. Although the regulations cover the whole of the EU, the power to approve or reject a notification rests solely with the national competent authority, in some cases with additional input from national scientific advisory bodies, other member states and the European Commission. It is also mandatory for the notifier to advertise the proposed release (usually in a national paper) within 10 days of submission, and for the national authority to provide the European Commission with a summary communicating the most important information in the application (SNIF, summary notification information format). The SNIF document is then made public, which in turn supports the transparency (openness) of the activities proposed -although this openness of precise field locations may then render field trials vulnerable to abuse by potential protestors. Information about all experimental releases authorized by the EU member states is available to all and can be accessed at the following URL: http://gmoinfo.jrc.ec.europa.eu/. According to Article 6.5 of Directive 2001/18/EC, the local (national and/or regional) authority must respond to the notification within 90 days by approving or rejecting it, if no additional information is requested from the notifier. Field trials are then subject to [annual] inspection throughout the life time of the trial by the GM Inspectorate; and for a set period of time post trial to ensure compliance.
Currently many EU countries have a negative position on GM plants and do not allow experimental field trials in their territory. Other countries are more open to the evaluation of this technology and while they allow field trials they impose strict compliance measures to avoid potential risks to the environment or human and animal health. Usually, specific conditions are imposed under which the field trial may go ahead, and these include: isolation distances and buffer strips to minimize outcrossing with the conventional counterpart or hybridization with sexually cross- Table 1 .
Overview compatible wild relatives; confinement measures to avoid the occurrence of volunteer plants in subsequent years originating from spilled seeds and/or vegetative plant parts during the trial and mixing of plant material in machinery during sowing, harvest and/or post-harvest operations [27] ; post-release follow-up to control potential volunteer plants occurring in subsequent years; and crop destruction. Plant material from these trials cannot enter the food and feed chain and has to be destroyed at the end of the trial [28, 29, 30] . In the EU, 51 field trials with GM plants serving as production platform for pharmaceutical or industrial products have been notified since 1995 (see Table 1 ). However, Europe has yet to witness the commercial application of PMP technology, although some pharmaceutical proteins (gastric lipase, lactoferrin) have entered phase I and II clinical trials [31, 32] .
Regulatory Requirements for PMP in Europe
There is currently no 'natural' home for the start to finish regulation of PMP/PMIs. Their regulation in Europe therefore falls to a number of regulatory bodies ( Table 2 ). PMPs will need to adhere to the regulations that cover the contained use of GMOs (2009/41/EC), for the early laboratory R&D phase, as well as covering GM material used in bioreactors and the growth of whole plants for PMF in contained facilities such as glass-houses. For some PMP products, where a therapeutic protein is considered 'high risk' because it could result in adverse effects if inadvertently eaten, regulatory approval would only be granted if crops were grown under containment conditions. PMP producing plants grown under containment conditions are likely to face fewer regulatory hurdles than field-grown PMP producing plants because the risk to the environment is lower.
Regulatory oversight for PMF in the field is covered by Directive 2001/18/EC, which regulates the deliberate release into the environment of GMOs. Part B of this Directive regulates the experimental field release (for which Europe has seen a number of notifications for PMF experimental release (see Table 1 ), although far behind the numbers for US). Part C of this Directive would regulate the import, cultivation, processing and marketing for commercial purposes. The EFSA, who oversees the assessment of GM plants to be deliberately released into the environment, published guidance notes in 2009 on the risk assessment of genetically modified plants used for non-food or non-feed purposes [3] including GM plants as production platform for PMI/PMP.
Europe has yet to see any Part C application for a commercial scale field release of a GM crop for PMF. Indeed, Europe in general falls far behind the rest of the world in approvals of GM crops for cultivation, with only two products being approved in the last 14 years for cultivation (insect resistant maize (MON810) and a modified starch potato (Amflora)). The maize MON810, and derivatives thereof (i.e., subsequent introduction of the insect resistant trait into maize breeding programs) are the only GM crops currently being cultivated in Europe. However, across Europe the political view point of cultivating GM crops is far from harmonious, with a number of Member States banning such cultivation (www.greenbiotech.org). Given the state of play surrounding the cultivation of agricultural GM crops, it is unlikely that we will see a pharma crop grown commercially in Europe any time soon.
When the plant cells/plants are harvested they then need to enter downstream processing in order to isolate the active substance, which can then enter cGMP facilities (discussed in detail in Schillberg et al., this issue). It is under cGMP that the formulation and assembly of a finished product, to enter clinical assessment, will take place and this will be in line with Regulation (EC) 726/2004 on 'Biopharmaceuticals and vaccines for human and veterinary use'. This Directive was originally set up for cell lines (e.g. CHO and bacterial cells), and it is argued that it needs to be refined to be more specific for plants [32, 33] . In particular, issues surrounding master and working cell banks, compliance with GMP and particularly issues regarding batch-to-batch consistency, standard operating procedures for different production systems and downstream processing requirements need to be addressed. The European Medicines Agency (EMEA) that oversees the assessment of biopharmaceuticals and vaccines, published guidance notes in 2006 on the 'quality of biological active substances produced by stable transgene expression in higher plants' [34] , which looks at such issues. As with all emerging technologies, it will be the early and first products to enter the approval/regulatory systems that will ultimately help shape and evolve the regulation surrounding PMPs.
When considering host plants in the context of biosafety and risk assessment, the better scientific option (e.g., plants with the highest yield, best protein stability, and better downstream processing ability) may not be the best choice of host from a biosafety and regulatory perspective.
The choice of host crop falls into three main categories: nonfood crops, food crops and non-cultivated crops (reviewed in [35] . Desirable crops from a biosafety perspective could include male sterile plants (such as male sterile lines of potato), crops with no wild relatives within the growing region (such as maize, tobacco or potato), or plants with heavy pollen (such as maize, barley and rice, again in countries with no wild relatives). A wealth of knowledge surrounds the cultivation of food crops and transformation procedures are well defined for a number of major crop species. However, the regulators may view such crops as less desirable because they represent major food crops, and therefore the risk of PMPs entering the food chain (even if only a perceived risk) would be higher than it would be when using non-food crops such as tobacco or non-cultivated crops, such as duckweed, that could be grown in containment. Nevertheless, the lack of toxic ingredients is an important advantage of food crops which should be taken into account.
The choice of expression site within the plant can also have biosafety implications. Targeting expression to the seed reduces the potential exposure of herbivores and other non-target organisms to pharmaceutical products expressed in the leaves as well as leaching of recombinant proteins into the environment from roots. However, one advantage of harvesting leaf tissue, rather than seeds or fruit, is that the plants do not need to flower, thereby reducing the risk of pollen and seed dispersal.
Some plants have already been recommended as not suitable for field production by regulatory bodies such as the US Animal and Plant Health Inspectorate (APHIS) and the Canadian regulatory authorities, these included oilseed rape (canola) and alfalfa. These plants are considered to be unsuitable because they are beepollinated, sexually compatible with local weed species and have multiple year seed dormancy. These traits therefore increase the risk of transgene spread and volunteer plants in subsequent crops. However, such crops may be considered as beneficial hosts if grown in containment.
Case Studies for Experimental Field Releases of PMP and PMI Producing Plants
In October 2008, the University of Rostock applied for the permission to release potatoes each carrying one of three different transgenes in a field trial planned from 2009 to 2011 at two sites (Thulendorf in Mecklenburg Pomerania and Üplingen in Saxony Anhalt). For each transgene, different events in different cultivars should be released in order to identify effects caused by somaclonal variation or cultivar, instead of the specific transgene ( Table 3) . The first transgene (35SctxBSEK) codes for the non-toxic B subunit (CTB) of Cholera toxin (CTA-CTB). CTB is one of the most potent natural adjuvants which functions as both mucosal and parenteral adjuvant [36, 37] . The natural CTB of Vibrio cholerae contains a specific signal peptide at its amino terminal end [38] that facilitates transport into the periplasmatic space, where the CTB monomers oligomerize [39] . In plants, both secretory and chloroplast-derived CTB expression have been demonstrated [40, 41] . Plant-derived fusion proteins of CTB expressing different antigens via the secretory pathway have been successfully used to induce specific immune responses and therapeutic effects [42] [43] [44] [45] [46] [47] [48] . No harmful effects could be detected when CTB was applied to mice [36, 40, 49, 50] . A very similar protein, Lt-B, was applied to humans without any deleterious effect [51] . The second transgene (35Svp60SEK) codes for an antigen supposed to lead to immunogenicity against the rabbit haemorrhagic disease (RHD) virus. RHD is an acute and highly infectious viral disease of the European rabbit (Oryctolagus cuniculus). Its capsid protein VP60, which forms a 27-40 nm virion with a structured surface of regularly arranged cup-shaped depressions [42] , was chosen as antigen. The third transgene (pPsbY-cphA) codes for a cyanophycin synthetase. Cyanophycin is a cyanobacterial reserve polymer composed of a poly--aspartic acid backbone with arginine residues linked via their -amino group to thecarboxyl group of each aspartate residue [52] [53] [54] . Mild hydrolysis of cyanophycin [55] results in homo-and copolymers of polyaspartate and additionally L-arginine as products. The latter one has a broad range of technical and medical applications, amongst others as a stimulator of the immune system [56] [57] [58] [59] [60] , growth increase by feeding [61, 62] , and as an inhibitor of tumour cell growth [63] . Polyaspartate is a soluble, non-toxic and biodegradable polycarboxylate [64] , which could replace the non-biodegradable polyacrylates in many of its industrial, agricultural, and medical applications [55, 65, 66] . Cyanophycin is synthesized via non-ribosomal polypeptide synthesis in many cyanobacteria and some other non photosynthetic bacteria [67, 68] . For cyanophycin synthesis only the cyanophycin synthetase, encoded by cphA, is necessary to catalyze the ATP dependent elongation of the cyanophycin primer by the consecutive addition of aspartic acid and arginine. All transgenic events carried the nptII gene as selectable marker. As controls, a transgenic line transformed with the empty vector carrying only the nptII gene was selected. In addition the cultivar 'Albatros' was used as near-isogenic variant (niv) and 'Desiree' as second potato cultivar.
The aim of the release was to identify potential effects of the three transgenes on the environment, to analyse the variability of transgene expression in comparison to greenhouse trials and to produce material for feeding studies. The number of tubers released is given in (Table 3) .
In October 2008 the application was sent to the German Federal Office of Consumer Protection and Food Safety (BVL) which is responsible for the approval of the trial. The application was a follow-up of a release that was carried out in 2005 to 2008, where transgenic potatoes carrying the same transgenes have already been released at the same sites. No signs of any detrimental effect have been observed. In December, the application was declared to be complete by BVL and this was announced in the federal bulletin as well as in local newspapers at the sites of release. In addition, the complete application was displayed for one month to the public at both locations and in Berlin in order to give everybody the chance to be informed. The whole process is expected to be finished in 90 days after the submission of the application, the time needed for corrections by the applicant and the month of public display is added. The approval was expected at least at the beginning of March 2009 in order to allow a timely release of the potatoes. Would follow the existing regulations developed for mammalian/ bacterial systems and draw guidance from EMEA guidance notes published on the 'quality of biological active substances produced by stable transgene expression in higher plants' [34] EMEA (assessment only), European Commission, Member States National competent authorities No additional information confirming the safety of the release of these potatoes was necessary. The location of the release had to be announced in the German 'Standortregister' (http://apps2.bvl.bund.de/stareg_web/showflaechen.do) in detail that it was easy to identify the place of release. Twelve additional measures were ordered by the BVL including that 1) during the release and the monitoring period, a 20 m wide area surrounding the trial had to be controlled every month for potential transgenic progeny; 2) after the release the area had to be loosened up 15 to 20 cm deep. Plugging was not permitted; 3) the area had to be monitored once a month in the following year in order to identify volunteers. If any transgenic volunteer were found in the area where the trial occurred, the monitoring period had to be prolonged for a second year. The tubers were planted by hand together with the controls and the area was surrounded by a 2 m high fence buried 30 cm deep into the soil. Watchmen were employed to protect the site, increasing the cost for the field trial drastically. Nevertheless, the field was attacked twice in 2009 and again in 2011. Fortunately, the destroyers were only able to tear some of the plants out of the soil, and in some cases it was possible to identify the plants so they could be replaced into the soil and the trial could be evaluated, at least partially.
CONDITIONS FOR MOLECULAR FARMING IN THE US 5.1. Regulatory Framework for Contained and Open Field use of Genetically Engineered (GE) Plants
In the US, laboratory practices using recombinant DNA (rDNA) must comply with National Institutes of Health (NIH) guidelines for recombinant DNA and these guidelines are administered by the Institutional Biosafety Committees of whatever entity is performing the research. However, in order for any impact to be realized from this research, these laboratory experiments must move ahead to the field or production arena. Commercialization has many hurdles including not only the science and associated intellectual property to protect the inventions, but also market realities and government regulations. As each engineered plant moves from the laboratory to scaled-up greenhouse production or to the field, issues emerge that trigger additional oversight for environmental release or ultimate use by humans.
The regulatory framework for genetically engineered plants in the United States has been discussed in many articles from several perspectives [69] [70] [71] . In contrast to the development of regulations in Europe, no specific legislation was enacted in the United States that provided guidance or directives relating to the regulation of genetically engineered plants. Rather June 26, 1986 ). This document included policy statements from the agencies involved as well as a proposed USDA regulation governing the introduction of organisms and products that are plant pests that were developed through genetic engineering [73] . Of significance and in contrast to European policies, an underlying principle of the US Coordinated Framework is that genetically engineered organisms are not inherently risky and regulatory requirements should focus on the product instead of the process used to derive the organism. Additionally, the existing agencies and laws were deemed sufficient to regulate this new technology and the agencies agreed to cooperate in the process. The resulting Coordinated Framework allowed (1) USDA to monitor planting and field testing as well as to regulate genetically engineered organisms that might be plant pests, (2) FDA to ensure the safety of most domestic and imported foods or feed, including genetically engineered foods, and to enforce pesticide tolerances established for food or feed by the EPA, and (3) the EPA to establish pesticide tolerances for food and feed and regulate genetically engineered organisms that contain pesticidal substances and the genetic material necessary for incorporation of pesticidal substances, new uses of existing pesticides, and novel micro-organisms [71, 74, 75] . Although these divisions of responsibility may be clear in theory, in practice the lines are often blurred as into whose purview a genetically engineered plant falls. The US policy decision to use existing laws, in effect, led to three different agencies with significant and often duplicative roles in the regulation of GM crops. Indeed, in most cases, different regulatory dossiers and data sets must be submitted to at least two US agencies, although these data sets are not mutually exclusive. Twenty-six years after the implementation of the US Coordinated Framework (i.e., in early 2012), the USDA, EPA, and FDA entered into a memorandum of understanding (77 Federal Register 5012, FRL-9328-7, MOU 225-11-0001) to permit information sharing between the three agencies. This may improve the overall coordination of regulation in the US although that remains to be seen.
Regulatory Considerations of the US Department of Agriculture -Animal Plant Health Inspection Service (APHIS)
The primary regulatory arm of the USDA that is relevant for plants and crops is the Animal and Plant Health Inspection Service (APHIS). The focus of APHIS is to protect US agriculture, food, and natural resources and it is in this context that it regulates GM crops [76] , specifically genetically engineered organisms capable of posing risks to plant or animal health.
The US Plant Protection Act (Title IV Public Law 106-224, 114 Statute 438, 7 U.S.C. §7701-7772) requires the USDA to prevent the introduction and dissemination of plant pests and weeds into the United States and provides specific authority to prohibit or restrict the importation, exportation, and interstate movement of plants, plant products, certain biological control organisms, noxious weeds, and plant pests [69] . APHIS regulations under 7 CFR §340.1 stipulate that any organism which has been altered or produced through genetic engineering is considered a regulated article if the donor organism, recipient organism, or vector or vector agent meets the definition of a plant pest, or is an unclassified organism and/or an organism whose classification is unknown, or any product which contains such an organism. Additionally, any other organism or product altered or produced through genetic engineering which the Administrator determines is a plant pest or has reason to believe is a plant pest is also regulated [77] . APHIS defines plant pests broadly to include any organisms that can damage or cause injury to plants or plant parts. Since many plant pathogens are used as vectors or promoters in genetic engineering, the plants produced from these agents are considered plant pests.
A GM crop developer must obtain APHIS authorization through either the permit process or notification process before a genetically engineered crop can be field tested or released into the environment. Movement and planting restrictions are imposed by permits while notification can be used in lieu of a permit when the plant is not considered a noxious weed [77] . Notifications, i.e., an expedited permitting process, are used primarily for field trial approval as well as importation and transport within the US of certain genetically engineered plants. To be eligible for a notification, specific criteria as well as designated performance and characteristics standards must be met. For example, among other things, the GM plant cannot be considered a noxious weed under USDA regulations or a weed in the area of release, the function of the genetic material must be known and its expression must not cause plant disease, the modification should not contain human or animal pathogenic sequence, and the crop cannot express a plant-made pharmaceutical or a plant-made industrial product [78] . Permits are used when the GE plant does not meet the requirements for notification.
In 2003, the USDA amended its regulations to require that introductions of plants genetically engineered to produce industrial compounds be conducted only under permit, i.e., not eligible for notification Docket No. 03-038-1, August 6, 2003). As with the notifications, developers must provide APHIS scientists with details about the nature of the GE organism. The main consideration for field trials is safety and prevention of unintended release in order to prevent spread of a potential plant pest to the environment. APHIS regulation 7 CFR Part 340.6 permits a crop developer to petition APHIS to evaluate submitted data to determine if a particular article presents a plant pest risk, and if not, should no longer be regulated [71, 77] . Once a developer has sufficient evidence that its GM product is no more risky than the equivalent non-GM parent, the developer may petition APHIS for a determination of nonregulated status to introduce the organism into US agriculture and commerce without APHIS oversight -i.e., to become "deregulated". Petitions must contain extensive data on details about plant biology, genetics, the nature and origin of the genetic material, expression of the gene product, disease and pest susceptibilities, field test reports and effects on other plants. In addition, data on the impact of the GM plant on other organisms including the potential for gene flow must be determined. Petitions are reviewed by APHIS with a focus on the potential for the GM plant to become a weed or plant pest [77, 78] . During the process of evaluation, APHIS at a minimum prepares an Environmental Assessment (EA) and a "Determination of Non-Regulated Status" as well as taking into consideration comments from the public.
While this review is not focused on the legal aspects of regulations, it warrants mentioning that APHIS has worked through several lawsuits filed by the Center for Food Safety (CFS) and the International Center for Technology Assessment (ICTA) [70] . These organizations alleged, in the early 2000's, that APHIS did not adequately evaluate the environmental risks of pharmaceuticalproducing GM crops using the directives of the National Environmental Policy Act (NEPA) of 1969. An environmental assessment prior to issuing permits in some instances would have prevented litigation over the field-testing of these crops. Current litigation involves the decisions by APHIS to de-regulate glyphosate-tolerant (GT) alfalfa and sugar beet. These complex cases allege that APHIS failed to consider outcrossing of GT alfalfa to organic crops or GT sugar beet to seed production sugar beet crops [70] . In each case, the de-regulation decision was accompanied by a "Finding of No Significant Impact" or FONSI. In response to these cases, the USDA prepared Final Environmental Impact Statements (FEIS) for GT alfalfa and sugar beet. USDA published the FEIS in December 2010 for the GT alfalfa lines J101 and J163 (APHIS-2007-0044-12532). These lines were determined to be unlikely to pose plant pest risks and thus were no longer considered regulated articles. In the FEIS published by the USDA in May 2012, the USDA found that GT sugar beets (H7-1) are not expected to become more invasive in natural environments or have any different effect on critical habitat than conventional sugar beets which do not establish or persist in the environment (APHIS-2010-0047-4658).
APHIS and New Breeding Technologies
In recent years, APHIS has taken steps to refine and limit its regulatory authority to only plants that are plant pests, were created with plant pests, or used a plant pest in the method to create the plant. This has resulted in the exemption from APHIS regulation several new breeding technologies.
Cibus Global (www.Cibus.com) received a green light from APHIS in 2004 when it learned that its herbicide tolerant canola developed with oligonucleotide-directed mutagenesis was not subject to regulation. In the March 2004 letter, APHIS indicated that it had no authority to regulate products created by mutagenesis techniques.
In May 2006, APHIS exempted from regulation a maize Zinc Finger Nuclease (ZFN) -deletion technology used by Dow AgroScience (May 26, 2010 letter). The ZFN-12 maize plants with induced deletions due to the use of zinc finger nuclease technology were not considered to be articles regulated by APHIS as ZFN-12 was not a plant pest and did not pose a plant pest risk.
APHIS clarified the scope of its regulatory authority in mid-2011 when it informed the public that a genetically engineered, herbicide tolerant Kentucky bluegrass developed by Scotts did not meet the definition of a regulated article (i.e., a plant pest) and thus was exempt from regulation by APHIS (APHIS-2011-0080). This conclusion was based on the fact that the Kentucky bluegrass itself is not a plant pest and that no organisms or the method used to create the variety were plant pests. In a July 2011 Factsheet regarding the action, APHIS made clear that it would exempt from regulation other GE organisms that are not a plant pest, are not made using plant pests, and when there is no reason to believe it is a plant pest.
While each of these decisions was made relative to a specific case, they indicate that APHIS will not regulate new breeding technologies in and of themselves. Rather, it appears that APHIS will continue to focus its regulatory requirements on plants that are a plant pest or that pose pest risk, without regard to the technology used to create the plant.
Regulatory Considerations of the Environmental Protection Agency (EPA)
The main role of the US Environmental Protection Agency (EPA) is to ensure that US citizens are protected from significant risks to health and that the environment is protected from invasive species. EPA regulations are designed to make US communities and ecosystems diverse, sustainable, and economically productive [76] . The regulatory activities of the EPA are governed by the requirements of specific environmental laws. These laws direct EPA to regulate many kinds of pollution, including pesticides, with a focus on how they affect different aspects of the environment. Environment is generally defined in these statutes as including human health, plant and animal life, water quality, and air quality [79] . The courts, the scientific community, and the regulatory community recognize that EPA should consider other factors along with science when it makes decisions about risk management [80] .
Under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) (7 U.S.C. §135 et seq., 1972), the EPA must determine if a new pesticide is able to perform its intended function without unreasonable adverse effects on human health and the environment (FIFRA §3) before it can be registered for use. Within the Coordinated Framework, these pesticides include genetically engineered pesticides or plant incorporated protectants (PIPs). PIPs, such as the Bacillus thuringiensis (Bt) toxin in corn, are considered pesticides under FIFRA because they are introduced into plants with the intention of preventing, destroying, repelling, or mitigating a pest (FI-FRA §2). Therefore, Plant-Made Pharpaceuticals are not regulated by EPA. In 2001, EPA published a rule that established the regulatory framework for PIPs and included (1) an exemption from FI-FRA requirements for those PIPs that are derived entirely through conventional breeding between sexually compatible plants and (2) an exemption from the requirement of the Federal Food, Drug, and Cosmetic Act (FFDCA) (21 U.S.C. § 301 et seq.) for the establishment of a residue tolerance level for pesticides [71] .
A developer of a crop that contains a pesticidal property that was not developed entirely through conventional breeding must submit an application to EPA to register a PIP. The EPA evaluates each submission to register a pesticidal substance produced by a a GM plant on a case-by-case basis, and requires data related to the product characterization which are similar to the data required by other agencies regarding the description of the GM plant and the details of its modification: i.e., organic source of the pesticidal gene construct (promoter, terminator, enhancer, marker genes and other inserted DNA). The dossier should include information on the biology of the plant, the stability of the genetically engineered DNA, and the anti-nutritional substances produced by the plant, among others.
Additionally, EPA requires data on mammalian toxicity, the effects on non-target organisms, environmental metabolism and an insect resistance management program for plants specifically expressing Bt products. Since the EPA focuses on the pesticidal properties, developers should include a full biochemical and amino acid description of the pesticidal protein. Since most PIPs are proteins, the issue of mammalian allergenicity is highly important. Acute digestibility assays and amino acid sequence homology are necessary to demonstrate absence of allergenicity concerns. EPA is also concerned with gene flow issues as they may result in expanded exposure to novel pesticidal substances as well as the environmental fate of PIP substances and the effect on non-target organisms [71] .
In addition to the requirement for a PIP to be registered before use unless it is exempted (as noted above), FIFRA section 7 requires that the producers of pesticides register the facilities where the pesticide is produced and report the amount produced. In contrast to APHIS requirements, experimental use permits are required, generally, for larger field trials (i.e., over 10 acres). In an effort to delay the onset of resistance to pesticides, EPA requires management strategies after commercialization. Farmers cultivating GM crops with PIPs are required to follow the appropriate insect resistance management (IRM) practices that are approved by EPA usually including refuge areas.
EPA and New Breeding Technologies
In March 2011, the EPA issued a Notice of Proposed RuleMaking (NPRM) that would specifically exempt from registration and the need for experimental use permits cisgenic PIPs (EPA-HQ-OPP-2009-0499; FRL-8873-5). Additionally, the proposed rule would contain proposed revisions to the data requirements for registration of PIPs or for an experimental use permit. In the NPRM, the EPA notified the public that it had sent the draft rule to the USDA and the FDA. The EPA has yet to finalize the proposed rule and submit to the Federal Register for comments.
Regulatory Considerations of the US Food and Drug Administration (FDA)
The Food and Drug Administration (FDA) is an agency within the US Department of Health and Human Services and is the primary agency with responsibility for ensuring the safety of food and feed, except for meat, poultry, and egg products which are regulated by the USDA. The FDA primarily assures the safety, effectiveness, and security of food, animal feed additives, as well as human and animal drugs under the regulatory authorities of the Federal Food, Drug, and Cosmetic Act (FFDCA) (21 U.S.C. § 301 et seq.) and the Public Health Service Act (42 U.S.C. § 201 et seq) [77] . The FDA also regulates tobacco products and helps the public obtain accurate, science-based information for their use of medicines and foods to improve their health (www.fda.org) [76] . Under the FFDCA, food and feed manufacturers must ensure the safety and proper labeling of their products. In contrast to the formal regulations implementing practices related to the regulation of genetically engineered plants that were issued by the USDA and the EPA, the FDA released guidance documents and draft guidances. Guidances merely reflect the current thinking of the FDA and are not legally binding on the agency or the crop developer; however, in practice, the recommendations in guidance documents are followed by developers.
In 1992, the FDA issued a policy statement (Federal Register, May 29, 1992, 57 FR 22984) indicating that it would regulate foods and feeds without regard to breeding method and it would not require special labeling of genetically engineered foods unless the composition of the food differed significantly from its conventional comparator [78, 81] The basic principle of the FDA policy is that the traits and characteristics of the foods/feeds should be the focus of safety regardless of the technique used to develop them. FDA regulates not only the presence of allergens but also any changes in composition, or levels of nutritional and anti-nutritional substances. The FFDCA requires premarket approval by the FDA of any food additive (i.e., substances intentionally added to food) that is not generally recognized as safe (GRAS) or otherwise exempt from premarket approval such as pesticides which are regulated by the EPA. Generally, most fruit, vegetables, or grain meet GRAS requirements as they have been consumed for many years. Thus, bioengineered foods composed of the same or nearly the same substances as their available counterpart (i.e., they are substantially equivalent) are not considered to be changed or adulterated [77, 78, 82] . Nonetheless, the FDA in 1992 recommended that developers voluntarily consult with FDA about bioengineered foods or PMPs or PMIs in food crops under development. In 2006 guidance, the FDA indicated that it expected developers of new bioengineered plant varieties to participate in the consultation process. Further, the FDA recommended developers consult with the FDA about the early food safety evaluation of new non-pesticidal proteins produced by new plant varieties for food use at an early stage and before there is a possibility that the new proteins might inadvertently enter the food supply. This recommendation was especially relevant to assuring the public of safety in the case of inadvertent entry of plant made pharmaceuticals into the food supply. Since 1992, all developers of GE foods have routinely consulted the FDA. A list of the FDA consultations is available on the FDA website: http://www.fda.gov/Food/Biotechnology/Submissions/default.htm; a list of the new protein consultations pursuant to the 2006 guidance is available at the FDA website: http://www.fda.gov/Food/Biotechnology/Submissions/ucm222595.htm.
The FDA is divided into centers that focus on different regulatory targets such as food, feed, or pharmaceuticals. Within these, the Center for Food Safety and Nutrition (CFSAN) regulates food and color additives and has been the primary regulatory location for GE crops [78] . CFSAN and the Center for Veterinary Medicine evaluate new foods and feed composition, respectively, including those from GE plants. The agency follows the requirements of the FFDCA with respect to human foods and animal feeds derived from new plant varieties and provides guidance to industry on scientific and regulatory issues related to these foods, including varieties that are developed using rDNA technology. Biological products and drugs for use in humans are regulated by the Center for Biologics
Developers are encouraged to submit a summary of the scientific and regulatory assessment of the food. The submission should include information regarding the genetic stability of the plant, nutritional and compositional analyses, allergenicity and toxicology studies as well as a complete assessment of the introduced gene products. In addition to these compositional analyses, the FDA might require information regarding the expected dietary exposure to any risk groups, such as children or immuno-suppressed patients, or particular religious or ethnic groups that might be overly exposed to the new food. It is important to remark that the FDA has not identified any new food or feed produced by rDNA technology with unexpected changes in composition or in the presence of allergens and other toxicants when compared to the naturally occurring comparator [83] .
After review, the FDA will issue a letter or memorandum indicating the characteristics of the new food and summarizing the possible safety concerns. They do not formally approve the new food or feed to be safe per se. Instead, they indicate it is not materially different from the unmodified version with respect to composition or safety as it is "as safe as its non-modified counterparts" [71] .
Specific Regulations for Molecular Farming
The USDA and FDA have included a few specific references to Plant-Made Pharmaceuticals (PMP) and Plant-Made Industrials (PMI) in policy statements, regulations, and proposed guidances. In its 1992 policy statement, the FDA recognized that new genetic modification techniques may develop plants that produce nonfood chemicals, such as polymers and pharmaceuticals. In crops not intended for food use, the developer is required to ensure that the nonfood-use varieties do not cross with food-use varieties. This requirement, though, is applied equally to crops developed through conventional breeding practices and those genetically engineered [81] . In instances where plants or materials derived from plants are used to make nonfood chemicals and also will be used for food, the crop developer should consult with FDA in advance for a determination of whether the nonfood chemical is a food additive that requires premarket approval.
As a result of several incidences where APHIS permits were violated and non-genetically engineered food crops became "adulterated", the USDA revised its regulations. In October 2002, ProdiGene, Inc. was investigated for failing to remove tasseled volunteer corn plants from a Nebraska field in which the Company grew a genetically engineered crop in the previous year. The field had been planted with soybeans in 2002. The volunteers may have contained a gene for a vaccine, but the volunteers could have been negative for the trait because at this stage of their development, the trait was segregating in a 1:1 ratio. Nevertheless, compliance documents required that all volunteers be pulled from the field prior to flowering and destroyed following standard operating procedures. Thus, pollen from the tasseling corn "adulterated" the soybeans in the field, making them unsellable. Also, some of the soybeans from this same field had been delivered to an elevator, and were mixed with soybeans in the elevator. This situation created another 500,000 bushels of adulterated soybeans. ProdiGene was fined for this compliance violation and made responsible for destroying the soybeans that had been adulterated (http://www. biotech.wisc.edu/Education/prodigene.html). In September 2002, a similar violation of permit conditions was found in a ProdiGene field at a 2001 Iowa test site. In this case, tasseling corn was found in a soybean field as well as a pile of volunteer corn plants that had been removed from the field previously. Each of these actions violated conditions of the permit. Under USDA supervision, ProdiGene destroyed 155 acres of surrounding corn at the site.
In response to these violations and to strengthen the confidence in the regulatory system, APHIS strengthened field-testing requirements for genetically engineered crop plants that express genes for out-put traits such as vaccines, pharmaceutical proteins, or industrial products. New safeguards were added that included comprehensive confinement procedures, performance standards and required monitoring/auditing practices for ensuring that outcrossing or commingling with other seeds and commodities cannot happen. In September 2002, the FDA and APHIS issued a draft guidance for industry on "Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals" (FDA-2002-D-0135-0001 ). While this draft guidance has never been implemented, it provides insight into USDA and FDA regulatory considerations related to PMP and PMIs. For example, the draft guidance recommends the implementation of measures that will prevent inadvertent mixing of a bioengineered pharmaceutical plant with plant material intended for food or feed, facilitate rapid and easy identification of the pharmaceutical plant including strategies that readily distinguish between the pharmaceutical plant and its food or feed counterpart.
Aside from this draft guidance and the revised APHIS fieldtesting requirements, no specific regulations have been implemented that are focused on PMPs or PMIs. The primary difference for PMPs and PMIs over input traits for GE crops entails the level of containment required when a crop expressing one of these output traits is in the field. For example, fields are subject to multiple inspections, the field must be surrounded by a 50-foot fallow zone, isolation distance from similar crops is strictly enforced with windpollinated crops at a larger distance than self-pollinated crops, equipment must be dedicated to the field trial for the entire field season then cleaned using USDA approved Standard Operating Procedures. Numerous reports are required before planting, during production and after harvest, including a volunteer monitoring report for the following year. No crop can be planted on the plot the following year so that volunteers can be destroyed.
Case Studies for Experimental Field Releases of PMP and PMI Producing Plants
A. Recombinant Cellulases in Transgenic Maize Seed: Cellulases (endo and exo) are the enzyme activities required in the greatest abundance for the conversion of lignocellulosic materials into simple sugars so that the sugars can be used for biobased products and biofuels. In addition to the huge volumes, because biofuels are a commodity product, the cost of these enzymes must be the lowest ever produced for an industrial process. Therefore, producing the cellulases in a plant system was a logical step for over-production for this cost-sensitive industry. The advantages of the plant seedbased system are large scale production without building infrastructure [84] and the ability to achieve high levels of expression [69] .
The genes for an endo-cellulase (E1 from Acidothermus cellulolyticus) and an exo-cellulase (cellobiohydrolase I, CBH I, from Trichoderma reesei) have been transformed into corn [85] . They are expressed from the maize globulin-1 promoter [86] and targeted either to the vacuole (E1) or the cell wall (CBH I). The vacuolar targeting sequence is from barley aleurain [87] , the cell wall targeting sequence is the barley alpha amylase signal sequence (BAASS) [88] , and the pinII terminator is from the potato proteinase inhibitor II gene [89] . The 35S promoter and terminator are from Cauliflower Mosaic Virus, and the selectable marker is moPAT, a maizeoptimized phosphinothricin N-acetyltransferase gene from Streptomyces viridochromogenes [90] offering resistance to the herbicide Bialaphos. Each of these elements is assembled into an Agrobacterium tumefaciens T-DNA unit between the left and right borders (Fig. 1) . Transformants that are resistant to the herbicide will have the cellulase transcription unit because transfer begins from the right border sequence and ensures that the gene of interest goes in first. Each of these elements and their source are relevant to the field trials and ultimately to the regulatory approval path taken by the developer.
Specific selected transgenic plants expressing the enzymes in seed were bred into elite germplasm lines to provide material for hybrid seed for production fields. Germplasm development is being carried out by Infinite Enzymes, LLC, in Arkansas, USA. Several permits have been issued for field-based crossing nurseries for this material.
Containment requirements: GE seed movement should be performed according to 7 CFR340.8: "All seeds shall be transported in a sealed plastic bag of at least 5 mil thickness, inside a sealed metal container, which shall be placed inside a second sealed metal container. Shock absorbing cushioning material shall be placed between the inner and outer metal containers. Each metal container shall be independently capable of protecting the seeds and preventing spillage or escape. Each set of metal containers shall then be enclosed in a sturdy outer shipping container constructed of corrugated fiberboard, corrugated cardboard, wood, or other material of equivalent strength." The developer may propose an alternate protocol to APHIS and have that approved for use instead of the above protocol in 340.8. The goal is to prevent spillage of GE seed in the event of an accident during transport.
GE corn grown outside should be isolated from seed production fields by 1320 feet (~400 m) and from grain production fields by 660 feet (~200 m). The entire nursery or production acreage should be surrounded by at least 4 rows of non-transgenic border corn as a pollen trap. An additional 50-foot fallow zone surrounds the border rows to allow space to monitor for volunteers during the growing season. Because production fields are open pollinated, additional isolation can be achieved by delayed planting so that pollen shed occurs at later times than other corn in the surrounding area. All personnel should be trained in the handling of GE materials using USDA-approved protocols. All equipment is cleaned using standard protocols after each use with GE material.
While in storage, all regulated articles covered under each permit should be kept in a locked storage facility with limited access to only authorized personnel. Storage containers must be identified as containing a genetically engineered regulated article. At least one sign stating "Authorized Personnel Only" must be posted in each area where the regulated article is stored. Upon completion of research, all regulated articles (except those retained for future studies) should be rendered non-viable by an appropriate method (e.g., heat or steam sterilization, bleach treatment, etc.). There is to be no further distribution of this regulated article under this permit without prior approval from State (intrastate movement) and Federal regulatory officials (interstate movement). APHIS/BRS and/or APHIS/PPQ personnel may conduct inspections of facilities and/or records at any time (taken directly from permit 12-109-101rm).
Reporting requirements: Several reports pertaining to the field trials are required during the lifetime of the permit. The first is a planting report that is due the 15 th day of the month following the planting of the regulated article and must include data describing the plants, the field conditions and the GPS coordinates. A second report, the Field Test Report, is due within six months after the expiration date of the permit. Field Test Reports provide the final status and observations at each location. APHIS considers these data reports as critical to assessment of plant pest risk and development of regulatory policies based on the best scientific evidence.
Finally, a volunteer monitoring report must be filed. The report should include the permit number, the state, the county, location name(s), location unique ID(s), dates when the field site and perimeter fallow zone were inspected for volunteers, number of volunteers observed, and any actions taken to remove or destroy volunteers. The final monitoring report is due no later than three months from the end of the volunteer monitoring period (taken directly from permit 12-109-101rm). During the field test, permittees are required to report any unusual occurrences, any unintended effects, or any accidental releases of the regulated articles.
B. Recombinant Hepatitis B Surface Antigen in Transgenic Maize Seed:
The production of vaccines in edible plant materials may allow the oral ingestion of a vaccine rather than administration by injection. To achieve this, the vaccine should be produced in an edible plant part such as corn seed. The advantages of such a system include ease of digestibility, a palatable delivery system, no allergenic agents, as well as seed providing a stable and bioencapsulated environment for the antigen [91] . In addition, preparations for oral delivery can be inert, pelleted products that do not require a cold chain, a major advantage for delivery to individuals in developing countries.
The Hepatitis B surface antigen (HBsAg) has been expressed in and characterized from recombinant maize seed [91] . The construct of interest that has been employed in mice feeding studies is expressed from the maize globulin-1 promoter and targeted to the apoplast using the maize-optimized barley alpha amylase signal sequence (BAASS) [88] similar to the cellulase construct above (Fig. 2) . The construct contains an additional transcription unit for the selectable marker encoded by the moPAT gene isolated from Streptomyces viridochromogenes which produces the enzyme phosphinothricin N-acetyltransferase (see cellulase case study and Fig. 1 ). This gene is constitutively expressed throughout the plant and is the same gene used for many transgenic plants including commercialized corn plants used in crop improvement. The surface antigen from the hepatitis B virus (HepBsAg) is a structural protein and has no enzymatic or toxic activity. This protein is currently used to make the commercial vaccine for hepatitis B (e.g. Recombivax® HB by Merck) and millions of people have been injected with this protein.
First generation seed from plants expressing this construct were bred into elite germplasm lines to improve agronomic growth characteristics and to produce higher-expressing HBsAg seed. Highexpressing individuals from the breeding program were selfpollinated to achieve homozygosity for HBsAg and complementary inbreds were crossed to produce hybrid seed for hybrid grain production (Hayden et al., in press, Plant Biotechnology Journal).
Using defatted germ (embryos) from these homozygous transgenic lines as a source of HBsAg feed material, mice that were previously injected with a commercial Hep B vaccine (Recombivax®) ingested the corn-derived material and produced high antibody titers of IgG and IgA from the orally administered boost [91] . The success of this study warrants continued growth of the corn lines with the view to produce large quantities for product development.
The field trial conditions for a plant-made pharmaceutical (PMP) are more stringent than the standard permit conditions cited above for the cellulases. The following information on containment and procedures is taken directly from the issued permit for the grow-out of the regulated pharmaceutical-producing corn lines. The distance from the edge of the field test site to reproductively compatible corn, Zea mays, will be by one of the following two methods:
• No corn grown within 1.0 mile of the field or • Corn tassels will be bagged, or removed, and no corn grown within 0.5 mile of the field test, and the transgenic corn will be planted no less than 28 days before or 28 days after any corn growing in a zone extending from 0.5 mile to 1 mile from the field test, and if tassels are bagged, plants will be checked weekly for intact bags. In this test site, two endangered species have been identified and measures to avoid harm to the California red-legged frog and tiger salamander must be taken. The permittee is required to monitor the field test site according to a "USFWS (US Fish and Wildlife Service) Measures to Avoid Harm to the California Red-Legged Frog and Tiger Salamander" and the "APHIS CRLF (CA redlegged frog) Information Sheet."
The procedures, processes, and safeguards used to prevent escape, dissemination, and persistence of the regulated article as described in the permit, in APHIS-approved Standard Operating Procedures (SOPs) and, in the supplemental permit conditions must be strictly followed. The permittee must maintain records sufficient to verify compliance with these procedures, including information regarding who performed the activity. Persons performing such activities shall have received training as described in a training program submitted to and approved by APHIS. These records are subject to examination by APHIS. APHIS/BRS and/or APHIS/PPQ (Plant Pest Quarantine) personnel may conduct inspections of the test site, facilities, and/or records at any time. APHIS may invite the FDA or State Regulatory Officials to participate in these inspections. Inspections will likely correspond to the beginning of the field test, mid-season or during flowering, and/or following harvest, and during the post-harvest monitoring period. Inspections will include examination of records to verify compliance with regulations and SOPs.
To ensure that transgenic plants are not inadvertently commingled with plants to be used for food or feed, a perimeter fallow zone of at least 50 ft. (unless a variance is granted by APHIS) must be maintained around the transgenic test site in which no crops are grown that would be used for food or feed. The permitted border rows of non-transgenic plants that are the same as, or sexuallycompatible with, the regulated article are considered part of the Fig. (1) . Plant transcription units driving expression of an exocellulase (CBH I) or an endocellulase (E1). The exocellulase is targeted to the cell wall with the barley alpha amylase signal sequence (BAASS) and transcription is driven by the maize globulin-1 promoter. The endocellulase is targeted to the vacuole using the barley aleurain signal sequence. Transcription is also from the maize globulin-1 promoter. The pinII terminator is from the potato proteinase inhibitor gene. Selection was achieved with phosphinothricin acetyl transferase conferring resistance to bialaphos. 35S promoter and terminator are from Cauliflower Mosaic Virus.
field test. The perimeter fallow zone shall start outside the border rows. The perimeter fallow zone shall be managed in a way that allows detection and destruction of volunteer plants that are the same as, or sexually compatible with, the transgenic plants.
To ensure that the regulated article is not inadvertently removed from the site, planting and harvesting equipment must be dedicated for use in the permitted test site(s) from the time of planting through the end of harvesting. After harvest, permittee will not be required to obtain APHIS authorization to use this equipment on APHIS-permitted sites (same sites or different sites) planted with same transgenic crop, with the target protein(s) authorized under this permit, in subsequent growing seasons under an extension of this permit or a different permit. Authorization is required from APHIS before this planting and harvesting equipment can be used on sites planted to crops not included under this permit. The permittee must notify APHIS/BRS and the State Regulatory Official at least 21 calendar days in advance of cleaning this equipment for this purpose so that APHIS may schedule an inspection to ensure that the equipment has been cleaned appropriately.
To minimize the risk of seed movement and commingling, equipment used for planting and harvesting, as well as other field equipment (e.g. tractors and tillage attachments, such as disks, plows, harrows, and subsoilers) used at any time from the time of planting through the post-harvest monitoring period must be cleaned in accordance with procedures submitted to and approved by APHIS before they are moved off of the test site. Equipment used to transport seeds or harvested material must be cleaned prior to loading and after transportation to the authorized site in accordance with procedures submitted to and approved by APHIS. Seed cleaning and drying must be performed in accordance with the procedures submitted to and approved by APHIS to confine the plant material and minimize the risk of seed loss, spillage, or commingling.
Dedicated facilities (locked or secured buildings, bins, or areas, posted as restricted to authorized personnel only) must be used for storage of equipment and regulated articles for the duration of the field test. Before returning these facilities to general use, they must be cleaned in accordance with procedures submitted to and approved by APHIS. The permittee must notify APHIS/BRS and the State Regulatory Official at least 21 calendar days in advance to allow for APHIS to schedule an inspection to ensure that the facilities have been cleaned appropriately. APHIS authorization should be received before facilities are returned to general use.
The field test site including the perimeter fallow zone must be monitored for the presence of volunteer corn plants for one year after termination of the field test on a monthly basis. Production of food and feed crops at the field test site and the perimeter fallow zone is restricted during the growing season that follows harvest or termination of the field test. Permission must be obtained from APHIS/BRS prior to planting any food or feed crop at the field test site and perimeter fallow zone during the post-harvest monitoring period. Requests for such permission are not encouraged and will not be granted in cases where there is a reasonable potential for plant material derived from, or originating from, the regulated articles to become mixed with the proposed food or feed crop during harvesting.
Reports and notices are required to be submitted at various intervals during the field test. At least 7 calendar days before planting, a Pre-Planting notice that includes information for each field test site should be submitted. A planting or environmental release report is the second report due to BRS. Planting reports must be submitted to BRS by the 15th of the month following the month in which the environmental release was started As above, ample data to describe the planting site and plants involved.
A third report is the Pre-Harvest/Termination Notice. At least 21 calendar days prior to the anticipated harvest or termination, the permittee must submit a Notice indicating the planned date of harvest or termination and the contact information for each field test site. For multiple harvests, the notice must be submitted prior to the initial harvest.
The two final reports are the Field Test Report and the Volunteer Monitoring Report. Within six months after the expiration date of the permit, the permittee is required to submit a Field Test Report. Field Test Reports provide the final status and observations at each location.
APHIS encourages the inclusion of other types of data if the applicant anticipates submission of a petition for determination of non-regulated status for their regulated article. APHIS considers these data reports as critical to our assessment of plant pest risk and development of regulatory policies based on the best scientific evidence. Failure by an applicant to provide data reports in a timely manner for a field trial may result in the withholding of permission by APHIS for future field trials.
The Volunteer Monitoring Report must include the statistics on the trial as for the Field Test Report. In addition it should include dates when the field site and perimeter fallow zone were inspected for volunteers, number of volunteers observed, and any actions taken to remove or destroy volunteers. The final monitoring report is due no later than three months from the end of the volunteer monitoring period.
In cases where a regulated article is stored on a production site, a report must be filed with APHIS each year the regulated article remains in storage at the production site. The report, which must include the permit number, storage location, crop, event, and quantity of each regulated article, must be filed prior to the anniversary of the expiration date of the permit under which the regulated article was produced.
C. Glucocerebrosidase -the first plant-made pharmaceutical to receive FDA approval for systemic administration. As a third example, it is worth mentioning the lysosomal enzyme replacement therapeutic, glucocerebrosidase, produced in plants. This enzyme was first produced in transgenic tobacco in the early 1990's in the Cramer group at CropTech Corp. partnering with Virginia Tech University. Glucocerebrosidase is deficient or lacking in patients with the lysosomal storage disorder referred to as Gaucher's syndrome, an orphan disease with fewer than 200,000 patients worldwide. Enzyme replacement therapy is the only feasible treatment, Fig. (2) . Plant transcription units driving expression of Hepatitis B Virus "S" antigen. The S antigen is targeted to the cell wall with the barley alpha amylase signal sequence (BAASS) and transcription is driven by the maize globulin-1 promoter. The pinII terminator is from the potato proteinase inhibitor gene. Selection was achieved with phosphinothricin acetyl transferase conferring resistance to bialaphos. 35S promoter and terminator are from Cauliflower Mosaic Virus.
and current treatments based on bioproduction in mammalian cells have been described as the most expensive drug in the world. The production of this enzyme in plants is protected by USP# 5,929,304 to VA Tech and CropTech with inventors: David Radin, Carole Cramer, and Deb Weissenborn. The production of this enzyme in plants was licensed by Protalix in Israel in 2005, where the company produces the enzyme in carrot cell suspension culture. Initial clinical trials were also initiated in 2005. In 2009, Pfizer Pharmaceuticals licensed rights for worldwide commercialization of the product with Protalix retaining rights in Israel. On May 1, 2012, the FDA approved this drug for use in patients in the US, making it the first plant-made pharmaceutical drug approved for human systemic administration. Because it is produced in suspension cell culture, it will not be subject to field regulation.
DISCUSSION
In 2006 a poultry vaccine against Newcastle disease, developed by Dow Agrosciences, became the first PMP to gain regulatory approval by the US Agricultural department. Although this product was never marketed, it was a significant milestone for PMF in terms of challenging and road testing the current regulatory systems. In 2012, an enzyme for treating the rare hereditary Gaucher disease (Elelyso, developed by Protalix) became the first PMP for human use to gain regulatory approval by the US FDA. Both of these products were developed using plant cell suspensions grown in bioreactors (tobacco and carrot cells respectively). The choice of production system, i.e. the use of cell culture in contained bioreactors, was no doubt taken to ease the regulatory approval process; with cell culture systems being more familiar to the current Pharma industry (i.e. mammalian, and bacterial culture systems).
In the US, the recent regulatory approval of Enogen corn from Syngenta has paved the way for industrial protein/enzyme commercialization from plants grown in the field. Enogen corn contains a heat tolerant amylase in the starchy endosperm, allowing for reduced cost of saccharification during processing and subsequent ethanol production. Within the context of the US regulatory framework, industrial proteins/enzymes that are already commonly used in industry, such as amylase and cellulase, are considered to be low hazard and are not regulated as "industrials" but under traditional permit conditions, so do not appear in the lists of Pharmaceuticals, Industrials and Value-Added Proteins, as tallied in (Table 4) . Multiple field trials of these products -amylase and cellulase in particular, have been conducted without incident.
In the EU project 'Pharma Planta' (www.pharma-planta.net), the primary aim was to develop a PMP, gain a better understanding of downstream processing and cGMP compliance issues and take a formulated product all the way through the regulatory process to phase I clinical trials. Both a food (maize) and a non-food (tobacco) host system were investigated at the early stages of the program. The choice to focus on a non-food crop was partly led by the belief that regulators would favour non-food crops, as any potential risks to the food/feed chain would be minimal. The program also chose a contained growth production system of whole tobacco plants grown in glass houses, which therefore also avoided the issues of 'a deliberate release into the environment' that would have been associated with a small-scale experimental field trial (Part B of Directive [32] . However, to fully exploit the potential of PMF there is still a strong need for the regulatory authorities to develop a policy framework to address the issue of 'large scale', i.e. field-grown agricultural production of PMPs.
The placing on the market of a GM plant containing a substance to be subsequently isolated, purified and formulated into a medicinal or industrial product, needs a separate authorization from the European Commission under Part C of Directive 2001/18/EC. During the field trial stage (Part B of Directive 2001/18/EC) Member States shall ensure that no material derived from GMOs is placed on the market, unless in accordance with Part C of the Directive. The majority of GM plants used as a production platform for PMP and PMI will not be placed on the market and commercialized as varieties but will be grown on limited acreage by contract farmers. Therefore, the costly authorization under Part C, we argue, is not appropriate. On the other hand, the commercialization of medicinal or industrial products produced under part B conditions is not allowed in Europe. Therefore, amendments of Directive 2001/18/EC are necessary to allow the commercialization of products from GM plants which are grown under conditions to be defined (e.g. limited acreage, contract cropping, and confinement) without the need of an authorization under Part C.
It is likely that the first approval for field-grown PMP cultivation may favour the use of non-food crops initially. While non-food crops may not be the best scientific choice (in terms of highest yields, and ease of scale up), they are likely to be perceived as less of a burden for different production chains. The key concerns will be keeping the food/feed chain 'contamination free'. This will be of high importance, especially in Europe, where the issues surrounding the cultivation of GM agricultural crops remains a contentious concern.
Early during the debut of PMF, the assumption of many scientists was that the benefit of the products would redeem the bad press that GM plants were receiving. The early [agricultural] products from large biotechnology companies were mistrusted and directly benefitted farmers but not consumers. PMF, on the other hand, had the potential of being directly beneficial to the consumer -new vaccines, cheaper pharmaceuticals, and organic plastics, for example. However, because of the fears that were spread throughout the popular press of "Frankenfoods", many of those benefits are still on the horizon rather than in the marketplace. Although the benefits are now well documented [2] and the regulatory agencies are working with developers to make progress to the marketplace a safe reality, it will likely be several more years before widespread acceptance of these alternative uses of plants are realized.
In Europe, the current GM approvals systems for both the cultivation and the import of agricultural GM crops are already frustratingly slow and expensive. In the last 14 years only 2 GM crops for commercial cultivation have made it through the EU regulatory approvals.
It is unlikely, therefore, that we will see a pharma crop grown commercially in the field in Europe any time soon. Concerned stakeholders and also the PMP industry will need to work closely with the regulatory authorities to ensure that there is strict regulatory oversight of these products, in order to gain the trust and support of the public and investors alike. Early products to come through the PMP pipeline will ultimately help shape the regulatory systems, and containment-grown crops or bioreactors are likely to pave the way for larger scale field production.
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